CONTACT
+91 80 2808 2808
info@biocon.com

Biocon Sdn. Bhd. Enters Malaysia Book of Records as the First & the Largest Integrated Insulin Manufacturing Facility

  • Posted by: BIOCON

Bengaluru, India & Johor, Malaysia, August 5, 2022 –

Biocon Sdn. Bhd., Malaysia, a subsidiary of Biocon Biologics Ltd (BBL), is proud to announce that it has entered the prestigious Malaysia Book of Records.

The 562,000 sq. ft. facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR, which officially recognizes record-creating and record-breaking achievements in the fields of human endeavour, building & structures, transportation, arts & entertainment, business, sports & games, science & technology, nature etc. in Malaysia.

Kiran Kumar Gandhirajan, Site Head, Malaysia, said: “We are extremely proud and honoured to be named in the Malaysia Book of Records, which is a recognition of the scale of our operations in the region. As the only insulin manufacturer in Malaysia, we have been able to achieve insulin self-sufficiency and improve insulin access while providing savings to our partner, Ministry of Health (MoH), Malaysia. Through the insulins manufactured at this facility, Biocon Biologics is also making a difference to the lives of millions of people with diabetes worldwide in line with our aspiration of taking our biosimilar insulins to ‘one in five’ insulin-dependent patients.”

“I would like to acknowledge the remarkable work being done by the team in Malaysia to address the global need for high quality insulins at affordable prices through our Center of Excellence (CoE) for insulins in Malaysia,” he added.

Biocon Biologics has created a Center of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to manufacture a broad portfolio of regular, basal and rapid insulins. The state-of-the-art insulins facility in Johor is the first and only biopharmaceutical sterile injectables facility in Malaysia to receive U.S. Food and Drug Administration (FDA) and European Medicines Agency approvals. More recently, Biocon’s biosimilar insulin Glargine made at Malaysia received a historic U.S. FDA approval as the ‘first interchangeable biosimilar’.

Through Biocon Sdn Bhd, Biocon Biologics has set up Asia’s largest integrated insulin manufacturing and R&D facility in Malaysia at an investment of over USD 350 million. This is the largest foreign investment in biotechnology in Malaysia, reflecting Biocon Biologics’ commitment to put affordable life-changing insulins within the reach of patients across the world. Biocon Biologics is providing affordable access to these life-saving therapies to patients in many developed markets like U.S., EU, Australia, as well as many emerging market countries in the Middle East and Latin America through its scientifically validated, high quality human insulin and analog products manufactured at the facility in Johor, Malaysia.

Commercial operations at the facility commenced in 2016 when Biocon Biologics’ recombinant human insulin became the first locally manufactured biosimilar product approved for sale in Malaysia.

About Malaysia Book of Records

Malaysia Book of Records (MBR) is the official, record-keeping body of Malaysia that recognizes record-holders, record-breakers and record-creators in the country. MBR started as a nation building initiative towards Vision 2020 and has grown to be home to over 7,000 proudly Malaysian-made records today. The bilingual record book strives to give Malaysians and their incredible feats the recognition they deserve for pushing human potential to its limit.

About Biocon Biologics Limited

Biocon Biologics Ltd., a subsidiary of Biocon Ltd., is a unique, fully integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower costs of biologics therapies while improving healthcare outcomes. It has a strong research pipeline of biosimilar molecules across diabetes, oncology, immunology and other non-communicable diseases. Seven molecules from Biocon Biologics’ portfolio have been commercialized in key emerging markets and developed markets like U.S., EU, Australia, Canada, Japan. It has many firsts to its credit including the most recent U.S. FDA approval of the world’s first interchangeable biosimilar, awarded to its Insulin Glargine, which has been commercialized in the U.S. in 2021. Biocon Biologics has signed a strategic alliance with Serum Institute Life Sciences (subject to certain closing conditions) to address the inequitable access to life saving vaccines and biologics globally. With a team of over 5,000 people, Biocon Biologics is committed to transforming healthcare and transforming lives by enabling affordable access to millions of patients’ worldwide. Website: www.bioconbiologics.com; Follow us on Twitter: @BioconBiologics for company updates.

Author: BIOCON
Share
Previous Next
Close
Test Caption
Test Description goes like this